The BTA is a digital health consortium of executive leaders from across life science, pharmaceutical, academic medical institutions and healthcare providers including New York City Economic Development Corporation, Merck Global Health Innovation, Johnson & Johnson, Fund LLC, BDO, Atlas Venture, StartUp Health, CATALAIZE, Consummate Capital, EdgeOne Medical, Esplanade Ventures, FFF, and Northwell Health, all committed to improving health outcomes and care delivery through verified emerging technologies. The board is chaired by Bill Taranto, the CEO of the Merck Global Innovation Fund.
The BTA board meets every quarter. All members have the benefits of:
- Setting priorities to guide the development of research studies for selected digital health technologies
- Receiving exclusive access to investment and partnership opportunities with the latest digital health tech under development
- Gaining insights into the future of digital health by seeing the results of the verified and risk-reduced studies.
“I am personally delighted to welcome Pat as a new board member,” said Bill Taranto, CEO of Merck Global Health Innovation Fund and Chair of HITLAB BTA. “With her strong technical expertise coupled with her experience working in health and wellness, she is an ideal addition to the board. I look forward to working with her.”
“The work HITLAB is doing in the healthcare space reflects Colgate-Palmolive’s purpose to reimagine a healthier future for all. I am honored and excited to serve on the BTA board,” said Pat Verduin, Chief Technology Officer, Colgate-Palmolive. “I look forward to working with HITLAB and the board to further their mission and goals.”